Incubation period of Creutzfeldt–Jakob disease in human growth hormone recipients in France

Objective: To estimate the statistical distribution of the incubation period of Creutzfeldt–Jakob disease (CJD) in human growth hormone (hGH) recipients in France. Background: Published papers suggest that the median incubation period of hGH-related CJD is approximately 15 years, but there are as yet no statistical data that support this assertion. Methods: Of the 1,361 hGH recipients who were included in this study, 55 had developed CJD at the time of the study. Individual data on hGH treatment history were available. Different mathematical models were used to estimate the statistical distribution of the incubation period. One main feature of the models was to take into account the occurrence of future CJD cases. Results: Models showed that the mean incubation period was 9 to 10 years, and the 95th percentile of the distribution was 15 to 16 years. Data and models indicated that the incubation period was significantly shorter in homozygotes at codon 129 of the prion protein gene than in heterozygotes. Conclusions: The short mean incubation period of CJD in French hGH recipients may be due to high infectivity in hormone lots. Estimates of the 95th percentile indicate that the number of hGH-related CJD cases may continue to increase in the coming years.

[1]  C. Tribioli,et al.  Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL , 1998, Nature Genetics.

[2]  J. Laplanche,et al.  Molecular genetics of prion diseases in France , 1994, Neurology.

[3]  Andrew F. Hill,et al.  Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD , 1996, Nature.

[4]  A. Hofman,et al.  A new variant of Creutzfeldt-Jakob disease in the UK , 1996, The Lancet.

[5]  L. Billard,et al.  Incubation period of AIDS in patients infected via blood transfusion , 1987, Nature.

[6]  S. Cousens,et al.  Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent , 1997, Nature.

[7]  Y. Agid,et al.  Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France , 1996, Neurology.

[8]  D. Wysowski,et al.  Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. , 1991, JAMA.

[9]  P. Brown,et al.  "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease , 1992, The Lancet.

[10]  A. Alpérovitch,et al.  A Stastical Model to Identify the contaminated Lots Implicated in Latrogenic Transmision of Creutzfeldt-Jakob Disease among French Human Growth Hoermone Receipents , 1998 .

[11]  J J Goedert,et al.  Censoring in an epidemic with an application to hemophilia-associated AIDS. , 1989, Biometrics.

[12]  M. Palmer,et al.  Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease , 1991, The Lancet.

[13]  D. Costagliola,et al.  Incubation time for AIDS from French transfusion-associated cases , 1989, Nature.

[14]  R. G. Will,et al.  Predicting the CJD epidemic in humans , 1997, Nature.